13.2 Stimulant Withdrawal, Craving & Contingency Management
Key Takeaways
- Stimulant withdrawal is not life-threatening but produces a crash of hypersomnia, hyperphagia, profound dysphoria and suicidal ideation within 24 hours of the last dose.
- Suicide risk during the stimulant crash is the principal safety concern, and DSM-5-TR lists dysphoric mood as a required feature of stimulant withdrawal.
- Contingency management is the single most effective intervention for stimulant use disorder, with effect sizes larger than any pharmacotherapy tested to date.
- Effective contingency management requires immediate, escalating, reset-on-relapse reinforcement tied to an objectively verified target such as a stimulant-negative urine sample.
- Federal guidance has allowed higher incentive values than the historical 75 dollar per-patient-per-year ceiling that limited earlier programs, and low-value incentive schedules are a common reason contingency management fails in practice.
13.2 Stimulant Withdrawal, Craving & Contingency Management
Quick Answer: Stimulant withdrawal produces a crash beginning within hours: dysphoric mood (a required DSM-5-TR criterion) plus fatigue, vivid unpleasant dreams, insomnia or hypersomnia, increased appetite, and psychomotor retardation or agitation. It is not medically dangerous but carries genuine suicide risk. No medication is FDA-approved. Contingency management (CM) — tangible, immediate, escalating reinforcement for objectively verified stimulant-negative urine samples — is the most effective intervention available and should be offered to every patient with stimulant use disorder who can access it.
1. The Withdrawal Syndrome
| Phase | Timing | Features |
|---|---|---|
| Crash | Hours 0 to 72 (may extend to a week after a long methamphetamine binge) | Profound fatigue, hypersomnia, hyperphagia, dysphoria, vivid dreams, irritability; suicidal ideation peaks here |
| Early withdrawal | Days 3 to 10 | Anhedonia, poor concentration, sleep dysregulation, intense craving triggered by cues |
| Protracted | Weeks to months | Anhedonia, reduced motivation, episodic craving that incubates rather than fades |
DSM-5-TR stimulant withdrawal requires cessation or reduction of prolonged use, plus dysphoric mood and two or more of: fatigue; vivid unpleasant dreams; insomnia or hypersomnia; increased appetite; psychomotor retardation or agitation.
Exam trap: unlike alcohol and sedative withdrawal, stimulant withdrawal does not cause seizures, autonomic instability or delirium. A stimulant-using patient with tremor, tachycardia, diaphoresis and disorientation on day 2 of abstinence is withdrawing from something else — most often alcohol or a benzodiazepine — or has a medical cause.
Managing the crash
- Safety first: assess suicidal ideation explicitly at each contact through the first week. The dysphoria is neurochemically driven and patients often describe it as worse than any depression they have experienced.
- Sleep: allow the hypersomnia. Trazodone, mirtazapine or melatonin are reasonable if insomnia rather than hypersomnia predominates; avoid benzodiazepines and Z-drugs in a population with high sedative co-use.
- Nutrition and hydration: patients are often profoundly depleted after a binge. Refeed, check electrolytes, and screen for rhabdomyolysis if the binge was prolonged.
- Do not start an antidepressant reflexively. Most crash dysphoria resolves within one to two weeks. Persisting depressive symptoms beyond 2 to 4 weeks of abstinence warrant reassessment for an independent depressive disorder.
2. Contingency Management: Mechanism and Design
CM applies operant conditioning: a behavior that is objectively verified and immediately reinforced increases in frequency. In stimulant use disorder it consistently outperforms cognitive behavioral therapy, motivational interviewing, and every medication tested.
The design rules that determine whether CM works
| Principle | Requirement | Common implementation failure |
|---|---|---|
| Objective target | Reinforce a verifiable behavior — usually a stimulant-negative urine sample | Reinforcing self-reported abstinence or session attendance only |
| Immediacy | Deliver the reinforcer the same visit, within minutes of the result | Mailing a gift card two weeks later |
| Frequency | Test and reinforce 2 to 3 times weekly early in treatment | Weekly or monthly testing, which lets use go undetected and unreinforced |
| Escalation | Increase incentive value with each consecutive negative sample | Flat, low-value incentives |
| Reset | Return to the starting value after a positive or missed sample, with a rapid "recapture" path back up | Permanent loss of accrued value, which drives dropout |
| Magnitude | Total available value must be meaningful | Historically many federal programs capped incentives near 75 dollars per patient per year, a value repeatedly shown to be too low; updated federal guidance permits substantially higher limits |
Two common formats
- Voucher-based reinforcement: each negative sample earns a voucher of escalating value, exchangeable for goods or services (never cash equivalents that facilitate use).
- Prize-based (fishbowl) reinforcement: each negative sample earns draws from a bowl containing mostly small prizes with a few large ones, which lowers total program cost while preserving effect.
3. Other Non-Pharmacological Treatments With Evidence
| Approach | Description | Evidence position |
|---|---|---|
| Community Reinforcement Approach plus vouchers (CRA + vouchers) | Restructures the patient's environment so non-drug reinforcers — employment, relationships, recreation — compete with drug reinforcement, combined with CM | Strongest combined behavioral package |
| The Matrix Model | 16-week structured intensive outpatient program combining relapse prevention, family education, social support, urine testing and 12-step introduction; developed specifically for stimulant users | Well-supported; the standard structured stimulant IOP |
| Cognitive behavioral therapy | Functional analysis, coping skills, relapse prevention | Effective, smaller effect than CM; durable gains after treatment ends |
| Exercise-based interventions | Structured aerobic and resistance training | Emerging evidence for reduced use and improved mood in residential settings |
High-yield combination: CM produces the largest in-treatment effect, while CBT and CRA produce more durable post-treatment gains. Combining them is the defensible answer when a stem asks for the optimal non-pharmacological plan.
4. Addressing Common Staff Objections
The APRN frequently has to defend CM to colleagues and administrators. Three evidence-based responses:
- "We are paying people not to use drugs." CM reinforces a verified biological outcome the same way a diabetes program reinforces glycemic targets. The reinforcer is contingent on the outcome, not on attendance.
- "The effect disappears when incentives stop." In-treatment effects are large; post-treatment effects decay but remain above control. Pairing CM with CRA or CBT and with recovery supports extends the benefit.
- "We cannot afford it." Prize-based schedules cost a fraction of voucher schedules, and stimulant-related emergency and inpatient utilization dwarfs incentive costs.
On hospital day 2 after stopping a four-day methamphetamine binge, a patient is sleeping 16 hours a day, eating voraciously, and describes overwhelming hopelessness with passive suicidal ideation. Vital signs are normal and the patient is fully oriented. What is the APRN's priority?
A clinic reports that its contingency management program for methamphetamine use disorder "does not work." Patients receive a flat 5 dollar gift card mailed monthly for each negative urine sample, and samples are collected once every four weeks. Which redesign is most consistent with the evidence base?
Which statement best describes the relative durability of contingency management and cognitive behavioral therapy for stimulant use disorder?